Evidence map›Paper›PMID 40356631›Full record

ReviewFrontiers in neurology2025

Recent technology development in radiotherapy for intracranial meningiomas.

Rebecca Ungar, Joshua Kilian-Meneghin, Brett Eckroate, Sabin Motwani, Ning Yue, Ke Nie, Zhenyu Xiong, Yin Zhang

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca UngarDepartment or Physics and Astronomy, Rutgers University, Piscataway, NJ, United States.
Joshua Kilian-MeneghinDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Brett EckroateDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Sabin MotwaniDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Ning YueDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Ke NieDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Zhenyu XiongDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.
Yin ZhangDepartment of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meningiomas are the most common central nervous system (CNS) tumors in the United States. Radiotherapy plays an important role in the management of meningiomas and has been established as an effective means of local tumor control. The recent technology development in artificial intelligence, understanding of meningioma biology and molecular imaging, will likely impact the clinical management of meningiomas, including treatment efficacy, efficiency and safety. This review summarizes recent technological advances that may influence radiotherapy management for meningiomas, including external beam radiation therapy, proton therapy and brachytherapy.

Indexed as

artificial intelligencebrachytherapyCyberKnifeGammaKnifemeningiomasproton therapyradiotherapy

Identifiers

PMID40356631
PMCPMC12066285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.